{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["ctg-studies"],"not_rendered":{"external_links":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"ctg-studies","index":0,"n_rows":68,"n_cols":5,"rows_kept":68,"merged":[[1,0,27,0],[28,0,39,0],[40,0,67,0]],"flags":["formulas_cached_only"]}
["Target","NCT Number","Study Title","Interventions","Phases"]
["IDO","NCT05843448","IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer","BIOLOGICAL: PD-L1/IDO Peptide Vaccine|BIOLOGICAL: Pembrolizumab","PHASE1"]
[null,"NCT03915405","KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer","DRUG: KHK2455|DRUG: Avelumab","PHASE1"]
[null,"NCT05077709","IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC","DRUG: IO102-IO103 in combination with pembrolizumab","PHASE2"]
[null,"NCT03343613","A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors","DRUG: LY3381916|DRUG: LY3300054","PHASE1"]
[null,"NCT02460367","Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer","DRUG: Docetaxel|BIOLOGICAL: Tergenpumatucel-L|DRUG: Indoximod","PHASE1"]
[null,"NCT01685255","A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy","DRUG: Epacadostat|DRUG: tamoxifen","PHASE2"]
[null,"NCT02118285","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: NK cells|BIOLOGICAL: IL-2|DRUG: INCB024360","PHASE1"]
[null,"NCT04190498","Sleep Apnoea Syndrome and Hepatocellular Carcinoma","DIAGNOSTIC_TEST: Nocturnal oximetry"]
[null,"NCT03695250","BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer","DRUG: IDO1 Inhibitor BMS-986205|BIOLOGICAL: Nivolumab","PHASE1|PHASE2"]
[null,"NCT03361865","Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)","DRUG: Pembrolizumab|DRUG: Epacadostat|DRUG: Placebo","PHASE3"]
[null,"NCT02077881","Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer","DRUG: Nab-Paclitaxel|DRUG: Gemcitabine|DRUG: Indoximod","PHASE1|PHASE2"]
[null,"NCT03374488","Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma","DRUG: Pembrolizumab|DRUG: Epacadostat|DRUG: Placebo","PHASE3"]
[null,"NCT03348904","Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer","DRUG: Nivolumab|DRUG: Epacadostat|DRUG: Placebo|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Paclitaxel|DRUG: Pemetrexed","PHASE3"]
[null,"NCT03347123","A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)","DRUG: Epacadostat|DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Lirilumab","PHASE1|PHASE2"]
[null,"NCT03342352","Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)","DRUG: Nivolumab|DRUG: Epacadostat|DRUG: Placebo|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Cetuximab|DRUG: 5-Fluorouracil","PHASE3"]
[null,"NCT03854032","Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck","BIOLOGICAL: Nivolumab|BIOLOGICAL: IDO1 Inhibitor BMS-986205|PROCEDURE: Therapeutic Conventional Surgery|OTHER: Questionnaire Administration","PHASE2"]
[null,"NCT03896113","Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma","DRUG: Celecoxib 200mg capsule","PHASE2"]
[null,"NCT02166905","DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission","BIOLOGICAL: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|DRUG: Epacadostat|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Poly ICLC","PHASE1|PHASE2"]
[null,"NCT01982487","Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission","BIOLOGICAL: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|DRUG: IDO1 inhibitor INCB024360|OTHER: laboratory biomarker analysis|OTHER: pharmacological study","PHASE1|PHASE2"]
[null,"NCT05280314","Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA庐 in Patients With Resectable Tumors","DRUG: IO102-IO103|DRUG: Pembrolizumab KEYTRUDA庐","PHASE2"]
[null,"NCT02042430","Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","DRUG: Epacadostat|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Therapeutic Conventional Surgery","EARLY_PHASE1"]
[null,"NCT03260894","Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","DRUG: Pembrolizumab|DRUG: Epacadostat|DRUG: Sunitinib|DRUG: Pazopanib","PHASE3"]
[null,"NCT03322540","Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)","DRUG: Pembrolizumab|DRUG: Epacadostat|DRUG: Placebo","PHASE2"]
[null,"NCT03358472","Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)","DRUG: Pembrolizumab|DRUG: Epacadostat|DRUG: Cetuximab|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: 5-Fluorouracil","PHASE3"]
[null,"NCT03322566","A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)","DRUG: Pembrolizumab|DRUG: Epacadostat|DRUG: Platinum-based chemotherapy|DRUG: Placebo","PHASE2"]
[null,"NCT03325465","Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck","DRUG: Pembrolizumab|DRUG: Epacadostat","PHASE2"]
[null,"NCT04463771","Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.","DRUG: retifanlimab|DRUG: epacadostat|DRUG: pemigatinib|DRUG: INCAGN02385|DRUG: INCAGN02390","PHASE2"]
["GLS","NCT02071862","Study of the Glutaminase Inhibitor CB-839 in Solid Tumors","DRUG: CB-839|DRUG: Pac-CB|DRUG: CBE|DRUG: CB-Erl|DRUG: CBD|DRUG: CB-Cabo","PHASE1"]
[null,"NCT05521997","Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer","DRUG: Telaglenastat|RADIATION: Radiation treatment|DRUG: Cisplatin","PHASE2"]
[null,"NCT03944902","CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients","DRUG: Cohort 1: Dose Escalation|DRUG: Cohort 2: Dose Escalation","PHASE1"]
[null,"NCT03163667","CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)","DRUG: Placebo|DRUG: CB-839|DRUG: everolimus","PHASE2"]
[null,"NCT03428217","CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma","DRUG: CB-839|DRUG: Cabozantinib|DRUG: Placebo","PHASE2"]
[null,"NCT02771626","Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)","DRUG: CB-839|DRUG: Nivolumab","PHASE1|PHASE2"]
[null,"NCT03875313","Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors","DRUG: CB-839|DRUG: Talazoparib","PHASE1|PHASE2"]
[null,"NCT04250545","Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer","DRUG: Sapanisertib|DRUG: Telaglenastat Hydrochloride","PHASE1"]
[null,"NCT05688215","Zimberelimab and Quemliclustat in Combination with Chemotherapy for the Treatment of Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Core Biopsy|DRUG: Fluorouracil|DRUG: Irinotecan|DRUG: Leucovorin|DRUG: Leucovorin Calcium|DRUG: Oxaliplatin|DRUG: Quemliclustat|DRUG: Zimberelimab","PHASE1|PHASE2"]
[null,"NCT04265534","KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC","DRUG: Telaglenastat|DRUG: Carboplatin Chemotherapy|DRUG: Pemetrexed Chemotherapy|BIOLOGICAL: Pembrolizumab Immunotherapy|DRUG: Placebo|DIETARY_SUPPLEMENT: Folic acid 400 -1000 渭g|DIETARY_SUPPLEMENT: Vitamin B12 1000 渭g|DRUG: Dexamethasone 4 mg","PHASE2"]
[null,"NCT03831932","Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer","PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Elastography|DRUG: Osimertinib|PROCEDURE: Positron Emission Tomography|DRUG: Telaglenastat Hydrochloride|PROCEDURE: X-Ray Imaging","PHASE1|PHASE2"]
[null,"NCT04698681","NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial"]
["Arg","NCT02006030","Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","DRUG: ADI-PEG 20|DRUG: Transarterial chemoembolization","PHASE2"]
[null,"NCT03278444","Treatment of Advanced Hepatocellular Carcinoma","OTHER: Basic drugs therapy of HCC|DRUG: Arginine hydrochloride|DRUG: Trimetazidine hydrochloride","PHASE3"]
[null,"NCT02029690","Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin","DRUG: ADI-PEG 20","PHASE1"]
[null,"NCT02102022","Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma","DRUG: ADI-PEG 20 plus modified FOLFOX6","PHASE1|PHASE2"]
[null,"NCT02101593","Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer","DRUG: ADI-PEG 20","PHASE1"]
[null,"NCT06034977","Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma","DRUG: ADI-PEG20","PHASE2"]
[null,"NCT03236935","Phase Ib of L-NMMA and Pembrolizumab","DRUG: L-NMMA|DRUG: Pembrolizumab","PHASE1"]
[null,"NCT03274427","Treatment of Intermediate-stage Hepatocellular Carcinoma","DEVICE: Basic drugs therapy of HCC by TACE|DRUG: Arginine hydrochloride|DRUG: Trimetazidine hydrochloride","PHASE3"]
[null,"NCT03498222","Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin","DRUG: Atezolizumab|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: ADI PEG20","PHASE1"]
[null,"NCT01665183","Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma","DRUG: ADI-PEG 20","PHASE1"]
[null,"NCT05616624","ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers","DRUG: ADI-PEG 20|DRUG: Gemcitabine|DRUG: Docetaxel","PHASE1|PHASE2"]
[null,"NCT03950518","Novel Treatment of Advanced Hepatocellular Carcinoma","DRUG: Anlotinib Hydrochloride Capsules|DRUG: Arginine hydrochloride|DRUG: levamisole","PHASE3"]
[null,"NCT01287585","Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy","DRUG: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|DRUG: Placebo|OTHER: Best Supportive Care","PHASE3"]
[null,"NCT04965714","Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer","BIOLOGICAL: Nivolumab|BIOLOGICAL: Pegargiminase|PROCEDURE: Resection","PHASE2"]
[null,"NCT01266018","Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer","DRUG: ADI-PEG 20 (Arginine deiminase pegylated)","PHASE2"]
[null,"NCT05317819","Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma","DRUG: ADI-PEG20|OTHER: Placebo","PHASE3"]
[null,"NCT02285101","Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors","BIOLOGICAL: PEG-BCT-100","PHASE1"]
[null,"NCT01314755","A Trial of Perioperative Immune Enhancing Feed in Patients Undergoing Surgery for Head and Neck Cancer","DIETARY_SUPPLEMENT: IMPACT|DIETARY_SUPPLEMENT: An iso-caloric, iso-nitrogenous control feed","NA"]
[null,"NCT03449901","ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer","DRUG: pegylated arginine deiminase|DRUG: Gemcitabine|DRUG: Docetaxel|PROCEDURE: Tumor biopsy|PROCEDURE: Research blood draw","PHASE2"]
[null,"NCT00559156","Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy","DIETARY_SUPPLEMENT: arginine/omega-3 fatty acids/nucleotides oral supplement|DRUG: cisplatin|PROCEDURE: adjuvant therapy|RADIATION: radiation therapy","PHASE2"]
[null,"NCT00151671","Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer","DRUG: Oral Impact庐|DRUG: Placebo","PHASE2|PHASE3"]
[null,"NCT04001543","Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer","DIETARY_SUPPLEMENT: Immunomodulating oral supplementation|DIETARY_SUPPLEMENT: Sip feed control","NA"]
[null,"NCT01806675","18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy","DRUG: 18F-fludeoxyglucose (18F-FDG)|DRUG: 18F-FPPRGD2","PHASE1|PHASE2"]
[null,"NCT01256034","Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy","DIETARY_SUPPLEMENT: Oral IMPACT","PHASE4"]
[null,"NCT05498428","A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","DRUG: Amivantamab|DRUG: Lazertinib|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Direct Oral Anticoagulant (DOAC)|DRUG: Low Molecular Weight Heparin (LMWH)","PHASE2"]
[null,"NCT01256047","Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy","DIETARY_SUPPLEMENT: Oral IMPACT","PHASE4"]
[null,"NCT02277197","Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)","DRUG: Ficlatuzumab|DRUG: Cetuximab","PHASE1"]
[null,"NCT02277184","Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma","DRUG: Ficlatuzumab|DRUG: Cisplatin|RADIATION: Intensity Modulated Radiotherapy (IMRT)","PHASE1"]